STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Inclusion Criteria: * M or F 18 or older with histologically confirmed metastatic (Stage IV) melanoma of cutaneous origin * ECOG performance status of greater than or equal to 2 * Measurable disease per RECIST criteria * Received no more than 1 regimen of prior chemotherapy (unlimited immunotherapy regimens are allowed) * At least 4 weeks have passed since last chemotherapy or immunotherapy * At least 2 weeks have passed since last radiotherapy. * Life expectancy of greater than 12 weeks * Clinical lab values within protocol parameters Exclusion Criteria: * Female patients pregnant or lactating * Female patients of childbearing potential not using or not willing to use effective contraception * Presence of a second malignancy other than nonmelanoma skin cancer * Presence of a clinically significant and uncontrolled infection * Presence of clinically significant arrythmias * Presence of serious concurrent illness or other conditions that do not permit adequate follow-up and compliance with protocol * History of severe hypersensitivity reactions to taxanes * Use of any investigational agents within 4 weeks prior to the first dose of study drug